Materion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29

Materion Corporation to Announce Third Quarter 2025 Financial Results on October 29, 2025 Materion Corporation (NYSE: MTRN), a leading global provider of advanced materials solutions, has announced that it will release its financial results for the third quarter of 2025…

Read MoreMaterion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29

Ashland Expands Injectables Portfolio with High-Purity Sucrose and Low-Nitrite Excipients

Ashland is spotlighting multiple new and optimized pharmaceutical product offerings during CPHI Frankfurt, October 28-30 (booth 8.0Q48) and AAPS PharmSci 360, San Antonio, TX, November 9-12 (booth 2808). To respond to global customer needs, Ashland has introduced vialose™ sucrose, a…

Read MoreAshland Expands Injectables Portfolio with High-Purity Sucrose and Low-Nitrite Excipients

BASF Opens NPG Plant in Zhanjiang, Launches Low-Carbon NEOL® NPG

BASF expands its presence in China with a new high-efficiency NPG plant powered by renewable energy, delivering lower-carbon intermediates for eco-friendly coatings BASF’s Intermediates division has inaugurated a new neopentyl glycol (NPG) plant at the Verbund site in Zhanjiang, China. Following the start-up of the new plant with an annual production…

Read MoreBASF Opens NPG Plant in Zhanjiang, Launches Low-Carbon NEOL® NPG

Air Products Completes First Liquid Hydrogen Fill at World’s Largest Sphere at NASA

Air Products Completes Historic First Liquid Hydrogen Fill of World’s Largest Storage Sphere at NASA’s Kennedy Space Center Air Products (NYSE: APD), the global leader in hydrogen supply, announced a major milestone in its long-standing partnership with NASA: the successful…

Read MoreAir Products Completes First Liquid Hydrogen Fill at World’s Largest Sphere at NASA

Pimicotinib Treatment Shows Lasting Tumor Response and Improved Pain and Function in TGCT Patients

Merck Announces Promising Long-Term Results of Pimicotinib in Phase 3 MANEUVER Trial for TGCT Treatment Merck, a leading global science and technology company, has today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial. This pivotal…

Read MorePimicotinib Treatment Shows Lasting Tumor Response and Improved Pain and Function in TGCT Patients